Mace Rothenberg

CIK: 0001873988

Transaction Breakdown

Open Market Buys (P)2 (33.3%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)4 (66.7%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

TNGX

Tango Therapeutics, Inc.

Director

SRZN

Surrozen, Inc./DE

Director

Discretionary Trading P&L

Holdings

Transaction History (6 total)

TNGX
Tango Therapeutics, Inc.
Jun 5, 2026
Award(A)
Direct
4K shares-
SRZN
Surrozen, Inc./DE
May 13, 2026
Award(A)
Director Stock Option (right to buy)
Direct
5.6K shares-
TNGX
Tango Therapeutics, Inc.
Jun 5, 2025
Award(A)
Direct
6.3K shares-
SRZN
Surrozen, Inc./DE
May 14, 2025
Award(A)
Option (right to buy)
Direct
1.3K shares-
TNGX
Tango Therapeutics, Inc.
Nov 18, 2024
Purchase(P)
Direct
10K shares at avg. $3.78$38K
TNGX
Tango Therapeutics, Inc.
Nov 14, 2024
Purchase(P)
Direct
10K shares at avg. $3.62$36K

		Type	Shares	Price		Ownership
Jun 5, 2026	TNGX Tango Therapeutics, Inc.	Award(A)	4,000	-	$0	Direct
May 13, 2026	SRZN Surrozen, Inc./DE	Award(A) Director Stock Option (right to buy)	5,550	-	-	Direct
Jun 5, 2025	TNGX Tango Therapeutics, Inc.	Award(A)	6,250	-	-	Direct
May 14, 2025	SRZN Surrozen, Inc./DE	Award(A) Option (right to buy)	1,333	-	-	Direct
Nov 18, 2024	TNGX Tango Therapeutics, Inc.	Purchase(P)	10,000	$3.78	$37,800	Direct
Nov 14, 2024	TNGX Tango Therapeutics, Inc.	Purchase(P)	10,000	$3.62	$36,200	Direct

1-6 of 6 transactions

About Rothenberg Mace

Rothenberg Mace (SEC CIK 0001873988) files insider reports with the SEC as Director of Tango Therapeutics, Inc. (TNGX) and Director of Surrozen, Inc./DE (SRZN).

Signal8 holds 5 ownership filings by Rothenberg Mace, all Form 4s, filed between Nov 18, 2024 and Jun 8, 2026. Those filings report 6 transactions, from Nov 14, 2024 to Jun 5, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Rothenberg Mace's filings is in BOSTON, MA.

Recent filings by Rothenberg Mace

Jun 5, 2026: Grant or award of TNGX shares (Form 4, code A).
May 13, 2026: Grant or award of SRZN derivative securities (Form 4, code A).
Jun 5, 2025: Grant or award of TNGX shares (Form 4, code A).
May 14, 2025: Grant or award of SRZN derivative securities (Form 4, code A).
Nov 18, 2024: Open-market purchase of TNGX shares (Form 4, code P).

Other insiders filing for Tango Therapeutics, Inc. (TNGX)

Crystal Adam, President, R&D
Newcomb Jessica, Principal Accounting Officer
Azelby Robert, Director
Ketchum John B, Director
Calhoun Lesley Ann, Director
Lee Sung, Director

How to read Form 4 transaction codes